In December 2019, a sudden public health event, the novel coronavirus pneumonia epidemic, ravaged Wuhan[1]。 On February 11, 2020, the disease caused by its causing virus was named "COVID-19" by the World Health Organization (WHO). On February 22, 2020, the National Health Commission revised the English name of "novel coronavirus pneumonia" to "COVID-19", which was consistent with the WHO naming, while the Chinese name remained unchanged. Up to now, there are more than 70,000 confirmed cases in my country. According to literature reports, the proportion of severe patients is 13.8%, critical patients is 4.7%, and the overall crude mortality rate is about 2.3%[2]。 At present, the prevention and treatment of COVID-19 has entered a critical stage, and effective treatment of severe and critical patients is the key to reducing their mortality rate. The Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (Trial Sixth Edition) issued by the National Health Commission[3]And "Diagnosis and Treatment Plan for Severe and Critical Cases of Pneumonia Infected by Novel Coronavirus (Trial)"[4]All mentioned that in addition to active oxygen therapy and respiratory support, circulatory monitoring and support, and nutritional support therapy, it is also necessary to evaluate whether acute kidney injury (AKI) and multiple organ dysfunctional syndrome (MODS) are combined in time. For critical patients with high inflammatory response, blood purification technologies such as plasma exchange, adsorption, perfusion, and blood/plasmafiltration are feasible.
